Conatus Pharmaceuticals Inc. (CNAT)

[Theo]

Don't know either. Fwiw:" ...Mr. Scopa’s decision to resign from the Board did not result from any disagreement with the Company concerning any matter relating to its operations, policies or practices. In connection with this resignation, pursuant to the bylaws of the Company, the Board voted to decrease the size of the Board from seven to six members."

In his Bio: ... Mr. Scopa's has over 25 years of experience as an Advisor to growth companies in the biopharmaceuticals and medical devices markets. He has been a Director of TriVascular Technologies, Inc. since March 2008. He serves as a Director at True North Therapeutics, Inc., JapanBridge, Inc., Kalidex Pharmaceuticals, Inc., Nevro Corporation, Idun Pharmaceuticals Inc., Blade Therapeutics, Inc., and Astute Medical, Inc. He was Director of Conatus Pharmaceuticals Inc. from March 2011 to September 12, 2018. He has been a Director of Semma Therapeutics, Inc. since March 24, 2015. He serves as a Board Observer at Nevro Corporation. He served as an External Director at Solasia Pharma K.K. until May 23, 2016. He served as Director of iPierian, Inc.

In RED are his current positions (which he held simultaneously with CNAT). Perhaps at some point, he foresees there is or could be a conflict of interest of sorts? Just spitballing here....